Molecular Targeted Therapy Market Size to Exceed $99.4 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Molecular Targeted Therapy Market Grown from 2024 to 2025?#_x000D_
In recent times, there has been significant growth in the molecular targeted therapy market. This market is predicted to expand from $65.78 billion in 2024 to $71.64 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.9%. Factors crediting to the growth during the historic phase include a rise in chronic disease incidence, escalating demands for tailored medication, increased utilization of biomarkers in medication development, escalated adoption of monoclonal antibodies, and surging approval rates for cancer treatment therapies._x000D_
_x000D_
#What Growth Rate Is Anticipated for the Molecular Targeted Therapy Market in the Coming Years?#_x000D_
Anticipations are high for substantial expansion in the molecular targeted therapy market size in the approaching years. A growth to $99.4 billion is projected by 2029, with a compound annual growth rate (CAGR) of 8.5%. The predicted progression during the forecast period can be credited to surges in cancer research funding, an escalated demand for targeted immunotherapies, a boom in clinical trial activities in the precision medicine field, increased utilization of companion diagnostics, and improving healthcare accessibility in budding economies. The forecast period is also expected to witness significant trends such as developments in genomics technology, innovations in drug delivery systems, heightened investment into research and development, advances in molecular diagnostics, and the utilization of AI technology for the discovery of therapies._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp_x000D_
_x000D_
#Who Are the Leading Companies in the Molecular Targeted Therapy Market?#_x000D_
Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc._x000D_
_x000D_
#What Are the Key Drivers of the Molecular Targeted Therapy Market?#_x000D_
The expanding popularity of personalized medicine is predicted to boost the molecular targeted therapy market’s growth. Offering a bespoke healthcare approach, personalized medicine operates based on the individual’s genetic makeup, lifestyle, and environmental considerations. Its burgeoning presence is fueled by the growing availability of genetic information, making it possible to create treatments specifically for an individual’s genome, enhancing effectiveness, and reducing adverse effects. Personalized medicine facilitates molecular targeted therapy by examining a patient’s tumor for unique genetic mutations or biomarkers. This allows for the implementation of therapies that directly target those abnormalities, improving treatment accuracy and minimizing damage to healthy tissues. To illustrate, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases patients in 2023, showing a substantial increase from the previous six in 2022. Consequently, the emergence of personalized medicine is propelling the growth of the molecular targeted therapy market forward._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24609&type=smp_x000D_
_x000D_
#What Are the Key Market Segments in the Molecular Targeted Therapy Industry?#_x000D_
The molecular targeted therapy market covered in this report is segmented –_x000D_
_x000D_
1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy_x000D_
2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous_x000D_
3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications_x000D_
4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers_x000D_
_x000D_
Subsegments:_x000D_
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies_x000D_
2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors_x000D_
3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing_x000D_
4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy_x000D_
_x000D_
#What Are the Latest Trends in the Molecular Targeted Therapy Market?#_x000D_
Prominent players in the molecular targeted therapy market are concentrating on the evolution of superior products such as small molecule inhibitors to enhance results for patients affected by numerous cancers and chronic disease. Small molecule inhibitors are minuscule compounds capable of penetrating cells and blocking certain proteins that trigger disease. For instance, Amgen Inc., a pharmaceutical company from the US, launched Lumakras (sotorasib) in combination with Vectibix (panitumumab) in January 2025, which was approved by a US government organization, the US Food and Drug Administration (FDA). This release is tailored for patients who are adults having KRAS G12C-mutated metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as determined by an FDA-approved test. The approval stems from the Phase 3 CodeBreaK 300 trial that demonstrated that the combination more than doubled the time period of progression-free survival in comparison to the standard care investigated, making it the first targeted therapy to exhibit such advantage in this patient group resistant to chemotherapy._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Are the Key Regional Markets in the Molecular Targeted Therapy Industry?#_x000D_
North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24609_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the molecular targeted therapy market, and how is it changing globally?_x000D_
2. Who are the major companies in the molecular targeted therapy market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the molecular targeted therapy market right now?_x000D_
4. Which products or customer segments are growing the most in the molecular targeted therapy market?_x000D_
5. What factors are helping or slowing down the growth of the molecular targeted therapy market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 3156230293_x000D_
Asia +44 2071930708_x000D_
Europe +44 2071930708_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
